The BAMBI Knockout HeLa Polyclonal Cells comprise a heterogeneous population of HeLa cells engineered by CRISPR/Cas9 to disrupt the BAMBI gene. This polyclonal knockout cell pool serves as a loss-of-function model for investigating BAMBI??s role in TGF-?? and BMP signaling. The CRISPR/Cas9-mediated gene disruption eliminates BAMBI protein expression across the population, allowing researchers to examine pathway consequences without clonal isolation. The product is ready for immediate use in cellular assays and requires no further selection.
The HeLa host cell line is a human cervical adenocarcinoma epithelial line, originally derived from a patient and extensively employed in cancer research. It is HPV18-positive and functionally p53-inactivated, creating a genetic background that facilitates oncogenic studies. HeLa cells retain epithelial characteristics and can undergo EMT, making them a suitable system for examining how BAMBI knockout modulates TGF-??/BMP-driven phenotypic changes. Their widespread use and well-documented properties ensure high experimental reproducibility.
BAMBI functions as a transmembrane pseudoreceptor that competitively inhibits BMP and TGF-?? signaling by binding ligands and preventing their interaction with type I receptors. It interacts with BMP2, BMP4, and TGF-??1, and blocks signaling through BMPR1A/ALK3, BMPR1B/ALK6, and TGFBR1/ALK5. This antagonism reduces phosphorylation of SMAD1/5/8 and SMAD2/3, thereby attenuating downstream gene expression. BAMBI expression is itself regulated by the ??-catenin/TCF complex and AP-1, highlighting its integration with Wnt and TGF-?? superfamily pathways.
Disruption of BAMBI in HeLa cells is predicted to relieve inhibition of BMP and TGF-?? pathways, resulting in enhanced phosphorylation of SMAD1/5/8 and SMAD2/3 and altered transcription of target genes. Since HeLa cells harbor HPV oncoproteins that inactivate p53, this knockout model allows examination of crosstalk between hyperactive TGF-??/BMP signaling and HPV-driven oncogenic processes. Consequently, the cells are particularly useful for studying deregulated proliferation, apoptosis, and EMT, providing insight into BAMBI??s contribution to tumor progression.
This polyclonal knockout population is suited for signal transduction and oncology research, including Western blot analysis of phospho-SMAD levels, RT-qPCR profiling of TGF-??/BMP target genes, and SMAD-responsive luciferase reporter assays. Functional studies may employ scratch wound, transwell, and proliferation assays, alongside immunofluorescence for EMT markers like E-cadherin and vimentin. The cells support drug target validation in BAMBI-implicated malignancies such as colorectal, gastric, hepatocellular, and ovarian cancers, as well as fibrosis models. For technical inquiries, contact Ascent Research.
